A Phase 2 Randomized, Double-Blind, Dose-Response Efficacy and Safety Study of SCH 900271 Compared to Placebo in Subjects With Primary Hypercholesterolemia (Familial and Nonfamilial) or Mixed Hyperlipidemia.

Trial Profile

A Phase 2 Randomized, Double-Blind, Dose-Response Efficacy and Safety Study of SCH 900271 Compared to Placebo in Subjects With Primary Hypercholesterolemia (Familial and Nonfamilial) or Mixed Hyperlipidemia.

Completed
Phase of Trial: Phase II

Latest Information Update: 15 Jun 2017

At a glance

  • Drugs SCH 900271 (Primary)
  • Indications Hypercholesterolaemia; Hyperlipoproteinaemia type V
  • Focus Therapeutic Use
  • Sponsors Merck & Co
  • Most Recent Events

    • 27 Mar 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 16 Jan 2010 Planned end date changed from 1 Apr 2010 to 1 Feb 2010 as reported by ClinicalTrials.gov.
    • 25 Dec 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top